Moderna to Present at Upcoming Conferences in June 2023

CAMBRIDGE, MA / ACCESSWIRE / June 1, 2023 / Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming investor conferences:

• 2023 Jefferies Healthcare Conference on Thursday, June 8^th at 10:30 a.m. ET
• 44^th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 14^th at 4:40 p.m. PST

A live webcast of each presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.

About Moderna

In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio and integrated manufacturing facilities that allow for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology Fand manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past eight years. To learn more, visit www.modernatx.com.

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
[email protected]

SOURCE: Moderna, Inc.

You May Also Be Interested In

• Kultura Beverage Group Expands Executive Leadership Team with Appointment of Beverage Industry Veteran Cathy Popick
• Chinese Copper Smelters Switch to Scrap Amid Concentrate Shortages
• ELEKTROS Gains Market Visibility as Critical Minerals, Lithium and Next-Generation EV Charging Take Center Stage